Growth • Corcept Therapeutics
CORT
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
17,1%
CAGR Revenue 5Y
Revenue Compound Annual Growth Rate in the last 5 years.
4,2%
CAGR Op. Income 5Y
Operating Income Compound Annual Growth Rate in the last 5 years.
8,4%
CAGR Net Income 5Y
Net Income Compound Annual Growth Rate in the last 5 years.
9,8%
CAGR EPS 5Y
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
7,8%
CAGR OCF 5Y
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!